Literature DB >> 10916104

Effect of vitamin E-bonded membrane on the 8-hydroxy 2'-deoxyguanosine level in leukocyte DNA of hemodialysis patients.

D C Tarng1, T P Huang, T Y Liu, H W Chen, Y J Sung, Y H Wei.   

Abstract

BACKGROUND: 8-Hydroxy 2'-deoxyguanosine (8-OHdG) of leukocyte DNA has been identified as a surrogate marker of oxidative stress in chronic hemodialysis (HD) patients. In this study, we focused on the determinants of the 8-OHdG level in leukocyte DNA of HD patients. We further investigated the influence of vitamin E-modified, regenerated cellulose (CL-E) membrane on the oxidative DNA damage, intracellular reactive oxygen species (ROS) production of granulocytes, and plasma alpha-tocopherol concentration.
METHODS: 8-OHdG content in cellular DNA of leukocytes was measured by a high-performance liquid chromatography-electrochemical detection (HPLC-ECD) method. Intracellular production of ROS, H2O2 and O2-. were analyzed by flow cytometry in leukocytes with and without phorbol-12-myristate-13-acetate (PMA) stimulation before dialysis, as well as at 15 and 30 minutes of dialysis. Plasma alpha-tocopherol concentration was measured by a HPLC method, and the value of alpha-tocopherol was corrected by total blood lipid concentration.
RESULTS: In the prospective cross sectional study, the mean 8-OHdG level in leukocyte DNA was equally lower in the patients of the CL-E, polymethylmethacrylate (PMMA), and polysulfone (PS) groups as compared with the cellulosic group (ANOVA, P < 0.001). The leukocyte 8-OHdG level correlated negatively with plasma alpha-tocopherol and blood lipid-adjusted plasma alpha-tocopherol, but correlated positively with serum iron and percentage of transferrin saturation. Forward stepwise multiple regression showed that dialysis membrane type, serum iron, and blood lipid-adjusted plasma alpha-tocopherol were the independent determinants of the leukocyte 8-OHdG level in HD patients. Like synthetic membranes, granulocyte ROS production was less augmented during dialysis with the CL-E membrane as compared with the cellulose membrane. Exposure to cellulose membrane impaired intracellular ROS production of granulocytes in response to PMA challenge, whereas the CL-E and synthetic membranes improved the granulocyte responsiveness to PMA. In the longitudinal cross-over study, the 8-OHdG level significantly decreased, and blood lipid-adjusted plasma alpha-tocopherol increased after switching the cellulose membrane to CL-E or synthetic membrane for eight weeks. In contrast, the 8-OHdG level dramatically rose, and blood lipid-adjusted plasma alpha-tocopherol declined after shift of CL-E or synthetic membrane to the cellulose membrane.
CONCLUSIONS: CL-E membrane exhibited biocompatible and bioactive characteristics. Like synthetic membranes, treatment with a CL-E dialyzer effectively reduced the 8-OHdG content in leukocyte DNA, suppressed intracellular ROS production of granulocytes, and preserved the plasma level of vitamin E. It could further improve granulocyte responsiveness to a PMA challenge. Reduced DNA damage and improved immune function of leukocytes may reduce the cancer and infection risks in chronic HD patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10916104     DOI: 10.1046/j.1523-1755.2000.00228.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  15 in total

1.  GST M1 polymorphism associates with DNA oxidative damage and mortality among hemodialysis patients.

Authors:  Yi-Sheng Lin; Szu-Chun Hung; Yau-Huei Wei; Der-Cherng Tarng
Journal:  J Am Soc Nephrol       Date:  2008-12-03       Impact factor: 10.121

2.  The association of plasma prorenin level with an oxidative stress marker, 8-OHdG, in nondiabetic hemodialysis patients.

Authors:  Yoshiyuki Morishita; Shiho Hanawa; Takuya Miki; Taro Sugase; Yasuhiro Sugaya; Junko Chinda; Osamu Iimura; Sadao Tsunematsu; Kenichi Ishibashi; Eiji Kusano
Journal:  Clin Exp Nephrol       Date:  2011-01-15       Impact factor: 2.801

3.  The effects of 1-year treatment with a haemodiafiltration with on-line regeneration of ultrafiltrate (HFR) dialysis on biomarkers of oxidative stress in patients with chronic renal failure.

Authors:  B González-Diez; M Cavia; G Torres; P Abaigar; V Camarero; P Muñiz
Journal:  Mol Biol Rep       Date:  2011-05-21       Impact factor: 2.316

4.  Accumulation of plasma N-methyl-2-pyridone-5-carboxamide in patients with chronic renal failure.

Authors:  Ewa M Slominska; Ryszard T Smolenski; Marek Szolkiewicz; Neil Leaver; Boleslaw Rutkowski; H Anne Simmonds; Julian Swierczynski
Journal:  Mol Cell Biochem       Date:  2002-02       Impact factor: 3.396

5.  Development of vitamin E-modified polysulfone membrane dialyzers.

Authors:  Masatomi Sasaki
Journal:  J Artif Organs       Date:  2006       Impact factor: 1.731

6.  Beneficial effects of the heme oxygenase-1/carbon monoxide system in patients with severe sepsis/septic shock.

Authors:  Shoji Takaki; Naoshi Takeyama; Yuka Kajita; Teru Yabuki; Hiroki Noguchi; Yasuo Miki; Yasusuke Inoue; Takashi Nakagawa; Hiroshi Noguchi
Journal:  Intensive Care Med       Date:  2009-09-29       Impact factor: 17.440

7.  Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients.

Authors:  Ko-Lin Kuo; Szu-Chun Hung; Yau-Huei Wei; Der-Cherng Tarng
Journal:  J Am Soc Nephrol       Date:  2008-05-21       Impact factor: 10.121

8.  The blood compatibilities of blood purification membranes and other materials developed in Japan.

Authors:  Takaya Abe; Karen Kato; Tomoaki Fujioka; Tadao Akizawa
Journal:  Int J Biomater       Date:  2011-09-28

Review 9.  Antiatherogenic effects of vitamin E: the search for the Holy Grail.

Authors:  Dimitrios Kirmizis; Dimitrios Chatzidimitriou
Journal:  Vasc Health Risk Manag       Date:  2009-09-18

Review 10.  Oxidized extracellular DNA as a stress signal in human cells.

Authors:  Aleksei V Ermakov; Marina S Konkova; Svetlana V Kostyuk; Vera L Izevskaya; Ancha Baranova; Natalya N Veiko
Journal:  Oxid Med Cell Longev       Date:  2013-03-06       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.